Desai, Sanjal H. http://orcid.org/0000-0002-7892-2625
LaPlant, Betsy
Macon, William R.
King, Rebecca L.
Wang, Yucai http://orcid.org/0000-0002-1576-8341
Inwards, David J.
Micallef, Ivana
Johnston, Patrick B.
Porrata, Luis F.
Ansell, Stephen M. http://orcid.org/0000-0003-1244-6758
Habermann, Thomas M.
Witzig, Thomas E. http://orcid.org/0000-0002-4215-6500
Nowakowski, Grzegorz S. http://orcid.org/0000-0002-6955-9393
Funding for this research was provided by:
Celgene/BMS
Research Funding (to institution): Incyte, Innocare, Novartis, Genentech Advisory board (to institution): Eli Lilly
Research Funding: Bristol Myer Squibb (BMS), Seattle Genetics, Takeda, Al Therapeutics, Regeneron, Affimed, Trillium, ADC therapeutics
Consultancy: Celgene, MorphoSys, Abbvie, Incyte, Spectrum Research funding: Celgene, Acerta, Karyopharm Therapeutics, Immune Design
Consultancy: Celgene/BMS, MorphoSys, Ryvu, Kite, Kymera, Curis, Seattle Genetics Research Funding:Celgene/BMS, MorphoSys, Nanostring
Article History
Received: 10 May 2021
Revised: 16 July 2021
Accepted: 29 July 2021
First Online: 25 September 2021
Competing interests
: Yucai Wang: research funding from Incyte, Innocare, Novartis, Genentech and member of the advisory board of Eli Lilly; Stephen M. Ansell: research funding from Bristol Myer Squibb (BMS), Seattle Genetics, Takeda, Al Therapeutics, Regeneron, Affimed, Trillium, ADC therapeutics; Thomas E. Witzig: consultancy in Celgene, MorphoSys, Abbvie, Incyte, Spectrum, and research funding: Celgene, Acerta, Karyopharm Therapeutics, Immune Design; Grzegorz S. Nowakowski: consultancy in Celgene/BMS, MorphoSys, Ryvu, Kite, Kymera, Curis, Seattle Genetics and research funding from Celgene/BMS, MorphoSys, Nanostring; Rebecca L. King: research funding from BMS/Celgene. The remaining authors declare no competing interests.